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Abstract
Background: Benzoylmesaconine (BMA) is the main Aconitum alkaloid in Radix Aconiti Lateralis
Preparata (Fuzi, aconite roots) with potent pharmacological activities, such as analgesia and anti-
inflammation. The present study developed a simple and reliable method using BMA as a marker
compound for the quality control of processed aconite roots and their products.
Methods: After extraction, a high-performance liquid chromatography (HPLC) determination of
BMA was conducted on a RP-C18 column by gradient elution with acetonitrile and aqueous phase,
containing 0.1% phosphoric acid adjusted with triethylamine to pH 3.0.
Results: A distinct peak profile was obtained and separation of BMA was achieved. Method
validation showed that the relative standard deviations (RSDs) of the precision of BMA in all intra-
day and inter-day assays were less than 1.36%, and that the average recovery rate was 96.95%.
Quantitative analysis of BMA showed that the content of BMA varied significantly in processed
aconite roots and their products.
Conclusion: This HPLC method using BMA as a marker compound is applicable to the quality
control of processed aconite roots and their products.
Background
Plants of the genus Aconitum are widely distributed across
Asia and North America. For over two thousand years,
Radix Aconiti Lateralis Preparata (Fuzi, aconite roots) has
been used in China to relieve joint pain and treat rheu-
matic diseases [1]. Studies demonstrated some pharmaco-
logical effects of aconite roots, such as analgesia and anti-
inflammation [2,3]. Processing aconite roots is necessary
to remove the poisonous diester-diterpene type Aconitum
alkaloids including aconitine, mesaconitine and hypaco-
nitine. For example, before used in proprietary herbal
products, the toxicity of these alkaloids can be lowered by
hydrolysis into much less poisonous benzoylaconines
which are the products of deacetylation of the 8β-acetoxyl
[4]. Previously, we established a high-performance liquid
chromatography (HPLC) method for determining these
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three toxic Aconitum  alkaloids [5]. By comparing their
peak areas, we found that benzoylmesaconine (BMA, Fig-
ure 1), one of the benzoylaconines, was more abundant
than the other two alkaloids in most processed aconite
roots [5]. It was reported that BMA at the dosage of 30 mg/
kg (per oral) significantly increased the pain threshold in
rats. Its analgesic potency was as potent as that of aconite
roots at 1000 mg/kg (per oral) [6]. Recently, BMA was fur-
ther shown to have specific cellular immunological activ-
ities, antiviral and antifungal activities [7], antinociceptive
effects [8], and stimulating activities on cytokines secre-
tion [9]. Due to its abundance and pharmacology, BMA
was selected as a single marker compound for the evalua-
tion of the quality of the processed aconite roots and their
proprietary herbal products.
The present study developed a suitable analytical method
for identification and quantification of BMA to simplify
the quality control procedures. Several HPLC methods
have been reported [10], none of which is efficient. For
instance, the target compounds could not be efficiently
separated in acetonitrile. Tetrahydrofuran (THF) was used
as the organic component of the mobile phase, but THF
would damage the RP-C18 column when its percentage
was over 10% [10]. In our previous HPLC method, buffer
with a pH value around 10 was used as mobile phase and
a special RP-C18 column was required to stand such an
alkaline buffer (pH > 8) [5,11]. At the moment, gas chro-
matography-mass spectrometry (GC-MS) and liquid chro-
matography-mass spectrometry (LC-MS) methods are
applicable, but both require sophisticated sample prepa-
ration, such as pre-column derivation and solid phase
extraction (SPE) [12-14]. In the present study, we devel-
oped a simple and reliable HPLC method for quantitative
determination of BMA in processed aconite roots and
their products.
Methods
Processed aconite roots and their proprietary products
Nine batches of the processed aconite roots were pur-
chased from herbal medicine markets in Sichuan, Shanxi
and Guangdong provinces in China (Table 1).
The Chinese proprietary products containing processed
aconite roots used in this study included Guifulizhong Wan
(GW, Foshan Fengliaoxiang Pharmaceutical Co, Guang-
dong, China), Sanqisangyao Capsule (SC, Guangxi Yulin
Pharmaceutical Co, Guangxi, China), Haimabushen Wan
(HW, Tianjin Zhongxin Pharmaceutical Co, Tianjin,
China), and Jinguishenqi Wan (JW, Tongrentang Pharma-
ceutical Co, Beijing, China). The main indications of these
products are muscular disorders, joint pain and arthritis.
Qingfuguanjieshu Capsule (QC), a new antiarthritic herbal
preparation being developed in our research group
[15,16], was also used in the present study.
Chemicals and reagents
Acetonitrile was of HPLC grade (International Laboratory,
USA). Twenty-eight per cent (28%) ammonia solution
(AJAX Chemicals, Australia), 95% ethanol (UNI-CHEM,
Hong Kong, China), chloroform (TEDIA, USA), ethyl ace-
tate, triethylamine, 85% phosphoric acid, diethyl ether
anhydrous (International Laboratory, USA) and hydro-
chloric acid (Merck, Germany) were of guaranteed reagent
grade. Deionized water was prepared using a Millipore
water purification system (Millipore Corp, USA).
The reference standard for BMA was prepared from mesa-
conitine (National Institute for the Control of Pharma-
ceutical and Biological Products, China) which was
heated at 100°C in dioxane-water (1:1) for 6 hours and
purified by column chromatography and crystallization
[5,11]. The identity and purity (≥ 95%) of BMA were con-
firmed by TLC (thin-layer chromatography), HPLC, and
spectroscopy (1H-NMR and MS) [17].
Table 1: BMA content (μg/g) in processed aconite roots (n = 2)
Samples (batch no) Sample source Mean (SD) (μg/g)
FZ040525-s1 Sichuan province 13.4 (0.5)
FZ040525-s2 Sichuan province 33.5 (0.1)
FZ030113-01 Shanxi province 25.3 (0.1)
FZ030616-01 Sichuan province 46.2 (1.2)
FZ030902-01 Guangdong province 10.7 (0.3)
FZ040406-01 Guangdong province 79.1 (1.0)
FZ040406-03 Guangdong province 164.0 (3.6)
FZ040406-07 Guangdong province 2.9 (0.1)
FZ040406-11 Guangdong province 4.6 (0.1)
Chemical structure of benzoylmesaconine (BMA) Figure 1
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HPLC conditions
An Agilent 1100 series LC system (Hewlett Packard, USA)
was used in the study, which consisted of a G1311A qua-
ternary pump, a G1322A degasser, a G1315A diode-array
detector and a G1313A autosampler.
Alltima RP-C18 (ID 250 × 4.6 mm, particle size 5 μm, All-
tech Associates, Inc., USA) was used as the stationary
phase companied by Alltima RP-C18 guard column (ID
7.5 × 4.6 mm). Elution of the alkaloids was carried out
using a gradient of acetonitrile (A) and buffer solution (B,
containing 0.1% phosphoric acid and 0.1% triethyl-
amine, adjusted to pH 3.0 with triethylamine) at a flow-
rate of 1.0 ml/min. The gradient elution of the mobile
phase was 13–18 % A in 0–20 min, 18–21 % A in 20–40
min, 21–22 % A in 40–45 min and 22–70 % A in 45–50
min. Detection was carried out at 240 nm with a reference
wavelength of 550 nm at room temperature. The injection
volume was 20 μl for all HPLC runs.
Preparation of sample solutions
Processed aconite roots were pulverized into powder,
passed through a 0.45 mm sieve, and stored in a desicca-
tor. The powder (1.5 g) was extracted with 50% ethanol
three times (4.0 ml, 4.0 ml and 2.0 ml respectively and 60
min each time) by sonication (Branson 5210 Ultrasonica-
tor, Balkowitsch Enterprises, Inc., USA) at room tempera-
ture, and then vortexed for 2 min respectively. The
mixture was centrifuged for 10 min at 3000 rpm (Eppen-
dorf 5810 Centrifuge, Scios, Inc., USA). The supernatants
were combined and transferred to a 10.0 ml volumetric
flask, with 50% ethanol making up the volume.
Powdered pills or contents of capsules of the proprietary
products (approximately 1.0 g) were accurately weighed.
Each sample was dissolved in 10 ml of HCl solution (0.05
M) by sonication for 60 min, and extracted with ethyl ace-
tate three times (10 ml each time). The acidic aqueous
solution was separated and basified with 600 μl of 28%
ammonia solution and further extracted with 10 ml of
mixed solvents of diethyl ether and ethyl acetate (1:1)
three times by vortexing for 2 min. The resulting mixtures
were centrifuged at 3000 rpm (Eppendorf 5810 Centri-
fuge, Scios Inc, USA) for 5 min and the combined super-
natants were evaporated to dryness under air stream. The
residue was dissolved in 1.0 ml of HCl solution (0.01 M)
by sonication for 1 min.
Preparation of standard solutions
BMA was accurately weighed and dissolved in HCl solu-
tion (0.01 M) to produce a stock standard solution at a
final concentration of 0.4084 mg/ml. This stock solution
was used to prepare standard solutions for method valida-
tion and calibration curves. The standard solutions were
stored at 4°C and remained stable for at least one month.
Calibration curves were established at seven concentra-
tion (μg/ml) points of 4.08, 10.21, 20.42, 40.84, 81.68,
122.52 and 204.20 respectively. For recovery test, a stand-
ard solution was prepared at a concentration of 12.25 μg/
ml.
Validation of the HPLC method
Precision
Expressed as relative standard deviations (RSDs), preci-
sion was evaluated by HPLC runs with standard solutions
at three concentrations under the optimal condition five
times in one day for intra-day variation test and twice a
day on three consecutive days for inter-day variation test.
Repeatability
Six aliquots of QC were conducted for repeatability test.
The processing of the aliquots followed the same method
described in the section of preparation of sample solu-
tions. The RSDs of the six aliquots were calculated for
evaluation of repeatability.
Recovery
HCl solution (10 ml, 0.05 M) was added to accurately
weighted QC (approximately 0.1 g) in which the content
of BMA was known. The sample solution was spiked with
1000 μl of the standard solution of BMA for recovery test.
The processing of the prepared samples (n = 6) followed
the method described in the section of preparation of
sample solutions.
Statistical analysis
Data analysis, including calculation of standard deviation
(SD) and linear regression, was conducted using Excel
2003 (Microsoft, USA). P values less than 0.05 were con-
sidered as statistically significant.
Results and discussion
Optimization of HPLC conditions
The use of phosphoric acid (0.1 %) with triethylamine as
the mobile phase produced better symmetry of the peak in
the chromatogram. A gradient elution program was devel-
oped to isolate BMA and to determine the content of BMA
in the proprietary products. Figure 2 shows a chromato-
gram of BMA (35 μg/ml) in standard solution. Figure 3
shows a chromatogram (detection at 240 nm) of BMA in
50 % ethanol extract of processed aconite roots. The
results indicate that the retention time (43.5 min) of BMA
in processed aconite roots (Figure 3) and in QC prepara-
tion (Figure 4) was consistent with that of BMA in stand-
ard solution (Figure 2).
By adjusting the triethylamine content to obtain the pH
values from 2.3 to 5.6, we investigated the pH dependence
of the retention time. The results show BMA retention
time remained relatively stable in the range of 42–44 minChinese Medicine 2008, 3:6 http://www.cmjournal.org/content/3/1/6
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as pH value increased (Figure 5). Due to a long elution
time and drifting baseline at pH values below 2.6 and
above 4.9 respectively, the HPLC runs in the present study
were carried out at pH 3.0 for best effect.
Optimization of extraction conditions
Common extracting solvents including water and aque-
ous ethanol (95 %, 75 %, 50 % and 25 %) were evaluated
for their efficiency in extracting BMA from processed aco-
nite roots. Since BMA is an alkaloid, an acidic extraction
solvent (0.01 M HCl) was also tested. The results show
that the extraction efficiency of these solvents was in the
following order: 50 % ethanol > 25% ethanol > 0.01 M
HCl > 75 % ethanol > 95 % ethanol. For highest effi-
ciency, 50 % ethanol was selected for extracting BMA in
processed aconite roots in the present study (Table 2).
As a single-step extraction with 50 % ethanol contained
many impurities, we developed a multi-step extraction to
remove some non-alkaloid components in the extracts.
Powdered proprietary products were dissolved in 10 ml of
HCl solution (0.05 M) by sonication for 60 min, which
were subsequently extracted with ethyl acetate for three
An HPLC chromatogram of BMA standard solution Figure 2
An HPLC chromatogram of BMA standard solution.
An HPLC chromatogram of BMA in processed aconite roots  (batch no 040406-01) Figure 3
An HPLC chromatogram of BMA in processed aconite roots 
(batch no 040406-01).
An HPLC chromatogram of BMA in QC Figure 4
An HPLC chromatogram of BMA in QC.
Relation of pH and the retention time of BMA Figure 5
Relation of pH and the retention time of BMA.Chinese Medicine 2008, 3:6 http://www.cmjournal.org/content/3/1/6
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times (10 ml each time). The acidic aqueous solutions
were then basified with 600 μl of 28 % ammonia solution
and further extracted with 10 ml of mixed solvents of die-
thyl ether and ethyl acetate (1:1) for three times. The
recovery rate of BMA was 90.64% (SD 0.58%) when die-
thyl ether was the extraction solvent. The recovery rate was
nearly perfect when ethyl acetate was the extraction sol-
vent; however, there was a small interference peak at the
retention time of 43 min. Thus, a mixed solvent of diethyl
ether and ethyl acetate (1:1) was used, whereby the recov-
ery rate was 96.95% (SD 1.01%) and no interference peak
was observed.
Validation of the HPLC method
The BMA peaks in processed aconite roots and in their
proprietary products were identified through comparison
of the retention times and UV spectra with those of the ref-
erence standards. Peak purity was confirmed by data from
a photodiode array detector (DAD). Furthermore, a com-
parative study was carried out with QC samples and QC
without processed aconite roots (negative control). There
is no peak corresponding to BMA in the chromatogram of
the negative control (Figure 6).
The linearity of the BMA concentrations (μg/ml) versus
peak areas was investigated in the range of 4.08–204.20
μg/ml; the result is expressed as the value of the coefficient
of determination (R2). The following equation was
obtained: Y = 18.518X + 5.651 (R2 = 0.9998, P < 0.001).
The limit of detection, defined as the amount of the com-
pounds needed to produce a signal (S) at least three times
larger than noise (N), was determined to be 8 ng for BMA
with an injection volume of 20 μl.
The precision of the intra-day (five times per day) and
inter-day (twice a day for three consecutive days) data was
indicated by RSDs which were less than 1.36% for BMA at
three concentrations (Table 3). These results suggest that
BMA is stable in acidic solution (0.01 M HCl). The accu-
racy was determined by back calculation of precision sam-
ples at three concentrations against a calibration curve
prepared each day.
The RSDs of the repeatability test were less than 0.29% for
BMA at 132.8 μg/g (SD 0.4 μg/g) in the QC samples (n =
6). The average recovery rate obtained was 96.95% (SD
1.01%) with RSDs of 0.01% (n = 6). This chromato-
graphic system is suitable for quantitative determination
of BMA in processed aconite roots and their proprietary
products.
Quantitative determination of BMA
The content of BMA in the five proprietary products, and
nine batches of processed aconite roots were determined
using the established HPLC method described above. The
content of BMA (Tables 1 and 4) was calculated with the
regression equations obtained from the calibration
curves.
Significant variations in terms of BMA content were found
among different batches of processed aconite roots and
among different proprietary products (Tables 1 and 4).
Differences in species, places of origin, processing meth-
ods of the raw materials and pharmaceutical manufactur-
ing processes may all contribute to the variations.
As herbal products containing processed aconite roots are
increasingly used for anti-inflammation and analgesia,
simple and reliable methods for quality control of these
products are urgently needed. It was reported that BMA
was effective in anti-inflammation and analgesia in ani-
mals [2,6]. Thus, BMA was selected as a marker com-
pound to assess the quality of processed aconite roots and
their proprietary products.
Table 2: Efficiency of different solvents in extracting the content 
of BMA (μg/g) from processed aconite roots (n = 2)
Solvents Mean (SD) (μg/g) RSD (%)
0.01 M HCl 20.8 (0.3) 1.24%
25% ethanol 22.7 (0.0) 0.10%
50% ethanol 25.3 (0.1) 0.45%
75% ethanol 14.8 (0.3) 0.18%
95% ethanol 0.55 (0.06) 10.98%
Note: Sample FZ030113-01 was used in this experiment.
An HPLC chromatogram of QC product without processed  aconite roots (negative control) Figure 6
An HPLC chromatogram of QC product without processed 
aconite roots (negative control).Chinese Medicine 2008, 3:6 http://www.cmjournal.org/content/3/1/6
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In the present study, extraction method was optimized.
Results from the recovery test show that the use of two sol-
vents is better than that of a single solvent in preparing
samples of proprietary products.
In the analysis of Aconitum  alkaloids using a reversed
phase C18 HPLC column, tailing peaks are usually caused
by the retention effects of free silanol groupings. Instead
of using THF as an organic solvent or basic buffer in the
mobile phase, we used triethylamine to improve separa-
tion and peak shapes. Moreover, this HPLC method
should be easily repeated in other labs. The present study
also indicates that the retention volumes of BMA
remained relatively unchanged over an acidic pH region
(Figure 5).
Conclusion
Method validation data indicate that the developed HPLC
method as described in this paper is reliable, reproducible
and accurate for the determination of BMA in processed
aconite roots and their products. The results also show
that the content of BMA varied significantly in different
batches of the processed aconite roots including five pro-
prietary products. This method is suitable for routine
assessment of the quality of processed aconite roots and
their products.
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